Alternativas al tratamiento con ciclofosfamida en la nefritis lúpica

Nefrologia

Volumn 26, Issue SUPPL.5, 2006, Pages 43-52

  Quereda, C ^a,c   Garcia Lopez F ^b,c   alvarez Rangel L E ^b,c   Galeano, C ^a,c   Pascual, J ^a,c   Praga, M ^c,d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c Hospital La Raza   (Mexico)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51849093228     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (41)

1. Albert DA. Does corticosteroid therapy affect survival of patients with SLE? Arthritis Rheum 1979;22:945-53.
2. Pollak VE, Dosekun AK. Evaluation of treatment in lupus nephritis: effects of prednisone. Am J Kidney Dis 1982;2 (Suppl 1):170-7.
3. Levels of Evidence of the Center for Evidence Based Medicine.- Universidad de Oxford: http: //www.cebm.net /levels_of_evidence.asp.
4. DT Felson, J Anderson. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984;311:1528-1533.
5. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29(2):193-199.
6. Flanc RS et al. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004;43:197-208.
7. Flanc RS et al.Tratamiento de la nefritis lúpica (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2005 Número 4. Oxford: Update Software Ltd. Disponible a: http: //www.update-software. com. (Traducida de The Cochrane Library, 2005 Issue 4. Chichester, UK: John Wiley).
8. Illei GG et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995- 1002.
9. Korbet SM et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904-914.
10. Chan TM et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-272.
11. Yee CS et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis Ann Rheum Dis 2004 May;63: 525-529.
12. Austin HA et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614.
13. Boumpas et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 1992;340:741-745.
14. llei GG et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med; 2001;135:248-257.
15. Gourley MF et al. Methyl-prednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Annals of internal medicine. 1996;125:549-557.
16. Houssiau FA et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
17. Chan TM et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 ;343:1156-1162.
18. Ginzler EM et al. Mycophenolate Mofetil or Intravenous Cyclophophamide for Lupus Nephritis. N Engl J Med 2005; 353:2219-2228.
19. Ong LM, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-510.
20. Cross J et al. Renal Association Clinical Trials Subcommittee. Mycophenolate mofetil for remission induction in severe lupus nephritis Nephron Clin Pract 2005;100:c92-1.
21. Pisoni CN et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005;32:1047-1052.
22. Alvarez L et al: Mycophenolate mofetil in lupus nephritis. Nefrologia 2002;22:24-32.
23. Banos I et al. Mycophenolate mofetil for lupus nephritis refractory to cyclophosphamide. Med Clin 2002;30;119:738-742.
24. Navas-Parejo A et al. Response to mycophenolate mofetil in a case of lupus nephropathy resistant tocyclophosphamide IV and cyclosporin. Nefrologia 2001;21(5):516-517.
25. Contreras G, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 Mar 4;350:971-980.
26. Chan TM et al. Hong Kong Nephrology Study Group.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.JASN 2005;16:1076-1084.
27. Houssiau FA et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis and rheumatism 2004;50:3934-3940.
28. Lewis EJ et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL. N Engl J Med. 1992;21;326:1373-1379.
29. Fu LW et al. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria British J Rheum 37:217-221.
30. Feutren G et al. Effects of cyclosporine in severe systemic lupus erythematosus J Pediatr 1987;111:1063-1068.
31. Tokuda M et al.Effect of low-dose cyclosporin A on systemic lupus erythematosus diseaseactivity. Arthritis Rheum 1994;37: 551-558.
32. Dammacco F et al. A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 2000;30:67-73.
33. Yin PD, Yang XY. A clinical study on low dose cyclosporin A in the treatment of lupus nephritis. Zhonghua nei ke za zhi [Chinese journal of internal medicine]. 1994; 33: 684-686.
34. Fever H et al. Ciclosporin in the treatment of lupus nephritis.Am J Nephrol. 1989;9 Suppl 1:57-60.
35. Manger K et al.Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. J Rheumatol 1996;35:669-675.
36. Tam LS et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998;91:573-580.
37. Dostal C et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 7 1998; 7:29-36.
38. Caccavo D et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997;40:27-35.
39. Mok CC et al.Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813-817.
40. Sfikakis PP et al. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future Current Opinion in Rheumatology 2005;17:550-557.
41. Thatayatikom A, White JW. Rituximab: A promising therapy in Systemic Lupus Erytehmatosus. Autoinmmunity Rev 2006;5:18-24.